Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Antengene Corporation Limited
  6. Summary
    6996   KYG039571008

ANTENGENE CORPORATION LIMITED

(6996)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
13.66 13.46 13.3 12.92 12.9 Last
655000 566500 1408684 1274000 9554580 Volume
-2.98% -1.46% -1.19% -2.86% -0.15% Change
Estimated financial data (e)
Sales 2021 2,00 M 0,31 M 0,31 M
Net income 2021 -752 M -116 M -116 M
Net cash position 2021 3 307 M 511 M 511 M
P/E ratio 2021 -9,19x
Yield 2021 -
Sales 2022 179 M 27,7 M 27,7 M
Net income 2022 -730 M -113 M -113 M
Net cash position 2022 2 475 M 383 M 383 M
P/E ratio 2022 -9,36x
Yield 2022 -
Capitalization 7 194 M 1 113 M 1 113 M
EV / Sales 2021 1 944x
EV / Sales 2022 26,4x
Nbr of Employees 219
Free-Float 56,2%
More Financials
Company
Antengene Corporation Limited is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and... 
More about the company
Ratings of Antengene Corporation Limited
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about ANTENGENE CORPORATION LIMITED
09/15Antengene Selected as a Constituent of the FTSE Global Equity Index Series
DJ
09/03ANTENGENE : Cancer Treatment Gets Approval for Phase 1 Clinical Trial in Austral..
MT
08/23ANTENGENE : Gets Chinese Regulator Nod for Phase 2 Trial of Potential Myelofibro..
MT
08/23ANTENGENE : Announces Approval of the Phase II Study of Selinexor for the Treatm..
PR
08/23Antengene Corporation Limited Announces Approval of the Phase II Study of Sel..
CI
08/23Antengene Narrows H1 Loss on Lower Research and Development Costs
MT
08/20Antengene Corporation Limited Announces Unaudited Consolidated Earnings Resul..
CI
08/08Antengene Corporation Limited and MindRank AI Enter into Collaboration to Adv..
CI
08/02KARYOPHARM THERAPEUTICS : Partner Antengene Says Cancer Drug Xpovio Gets Approva..
MT
07/30ANTENGENE : Voluntary announcement approval of nda by the mfds for atg-010 (seli..
PU
07/30Antengene Corporation Limited Announces the Approval of NDA by the MFDS for A..
CI
07/26KARYOPHARM THERAPEUTICS : Says Selinexor Shows Potential Activity Against COVID-..
MT
07/21Antengene Announces The Approval by Human Research Ethics Committeein Austral..
CI
07/13ANTENGENE : Submits New Drug Application for Selinexor in Taiwan for the Treatme..
PR
07/06Antengene Announces Acceptance of IND Application in China for the Phase II C..
CI
More news
News in other languages on ANTENGENE CORPORATION LIMITED

- No features available -

More news
Chart ANTENGENE CORPORATION LIMITED
Duration : Period :
Antengene Corporation Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANTENGENE CORPORATION LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 10,72 CNY
Average target price 22,02 CNY
Spread / Average Target 105%
EPS Revisions
Managers and Directors
Jian Ming Mei Chairman & Chief Executive Officer
Donald Andrew Lung Chief Financial Officer & Executive Director
Bo Shan Chief Scientific Officer
Kevin Lynch Executive Director & Chief Medical Officer
Yiteng Liu Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ANTENGENE CORPORATION LIMITED-24.74%1 113
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850